- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Life Science Instrumentation Market by Technology (Spectroscopy, Chromatography, NGS, PCR, Microscopy, Centrifuge, Liquid Handling), Application (Diagnostic, Research), End User (Pharma-Biopharma, Food, Hospital, Academia, CRO) - Global Forecast to 2031
USD 92.53 BN
MARKET SIZE, 2031
CAGR 6.5%
(2025-2031)
500
REPORT PAGES
600
MARKET TABLES
LIFE SCIENCE INSTRUMENTATION MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global life science instrumentation market is projected to grow from USD 63.40 billion in 2026 to USD 92.53 billion by 2031, at a CAGR of 6.5% during the forecast period. The market was valued at USD 59.91 billion in 2025. The growing demand for advanced analytical technologies in drug discovery, genomics, and proteomics research, as well as increased investments in pharmaceutical and biotechnology R&D, is expected to drive market growth in the coming years.
KEY TAKEAWAYS
-
BY REGION
By region, the Asia Pacific market is expected to register the highest CAGR of 7.3% during the forecast period from 2025 to 2031.
-
BY TECHNOLOGY
By technology, the other technologies segment is expected to dominate the market, with a share of 28.1% in 2025.
-
BY APPLICATION
By application, the research applications segment accounted for the largest share of 63.8% in 2025.
-
BY END USER
By end user, the agriculture and food industries segment is expected to register the highest CAGR of 7.7% during the forecast period from 2025 to 2031.
-
COMPETITIVE LANDSCAPE - KEY PLAYERS
Major market players have adopted both organic and inorganic strategies, including partnerships and investments. Thermo Fisher Scientific Inc (US), Agilent Technologies Inc. (US), Shimadzu Corporation (Japan), Danaher Corporation (US), and Waters Corporation (US) are the key players in the life science instrumentation market. These market players are leveraging strategic partnerships, acquisitions, and strong R&D investments in automation and AI to expand their portfolios and strengthen their competitive position.
-
COMPETITIVE LANDSCAPE - STARTUPS/SMEs
bioMérieux (France), Illumina Inc. (US), Avantor Inc (US), Olympus Corporation (Japan), and Oxford Instruments (UK) are the key startups/SMEs in the life science instrumentation market. These market players are driving growth through continuous innovation in high-resolution imaging, integration of advanced automation and analytics, and expanding applications in nanotechnology and biological research.
The life science instrumentation market is driven by a growing focus on precision medicine, automation, and high-throughput analysis, which is accelerating the adoption of advanced instruments across clinical, academic, and industrial laboratories. Ongoing advancements in spectroscopy, chromatography, and molecular analysis, along with their expanding use in healthcare, food safety, and environmental testing, are further supporting market growth. In addition, strong government funding, stringent regulatory requirements, and the increasing integration of AI and digital technologies into laboratory workflows continue to strengthen the global market outlook.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
A major trend disruption in the life science instrumentation market is the rapid shift toward digitalization, automation, and AI-driven workflows, which is transforming how laboratories operate and deliver results. This shift is reshaping end-user expectations across healthcare, pharmaceuticals, food, and environmental sectors, driving demand for faster, more accurate, and data-integrated analytical solutions. At the same time, increasing regulatory scrutiny, sustainability requirements, and the move toward precision medicine are compelling organizations to upgrade to advanced, high-sensitivity instruments. These disruptions are ultimately pushing market players to innovate continuously while enabling end users to enhance efficiency, transparency, and overall value delivery.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Increasing investment in pharmaceutical R&D
-
Growing concerns regarding food contamination
RESTRAINTS
Impact
Level
-
Premium product pricing for instruments
-
Shortage of skilled professionals
OPPORTUNITIES
Impact
Level
-
Growing opportunities from CRO, CDMO, and CTL expansion
-
Broad applications of analytical instruments across industries
CHALLENGES
Impact
Level
-
Inadequate healthcare infrastructure in emerging economies
-
Data privacy concerns associated with NGS software
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Increasing investments in pharmaceutical research and development (R&D) are driving the market for life science instruments. Multinational pharmaceutical and biotech companies are expanding their manufacturing capabilities and research pipelines with support from both public and private funding. As a result of this growth, there is a rising demand for high-performance analytical, separation, imaging, and automation tools for applications such as cell therapy, proteomics, genomics, bioprocessing, and formulation development. The surge in R&D activities has led to a greater need for high-throughput screening, advanced molecular analysis, and data-driven process optimization. For instance, in October 2025, Merck began constructing a USD 3 billion Center of Excellence in Elkton, Virginia, to accelerate drug development. Similarly, AbbVie committed approximately USD 1.4 billion in April 2026 to establish a new R&D and manufacturing facility.
The life science instrumentation market is experiencing a trend toward premium pricing for advanced instruments. High-end systems such as mass spectrometers, chromatography platforms, and next-generation sequencing tools are priced significantly higher due to their superior precision, automation, and integration with artificial intelligence and advanced data analytics. This represents a shift to value-based pricing, where customers are willing to pay a premium for enhanced performance, reliability, regulatory compliance, and high-quality data output. Additionally, the increasing demand for high-throughput capabilities and comprehensive workflow solutions further justifies these higher price points, especially among pharmaceutical, biotechnology, and clinical research organizations that are seeking efficiency and a competitive edge.
The rapid expansion of CROs, CDMOs, and CTLs is driven by the increasing outsourcing of research, manufacturing, and quality testing by biopharma and biotech companies. This shift has created a strong demand for advanced analytical, imaging, separation, and automation instruments, as these service providers depend on high-precision and high-throughput technologies to deliver faster, cost-effective, and regulatory-compliant results. Consequently, instrument manufacturers are presented with significant opportunities to supply next-generation, scalable, and integrated solutions that enhance productivity, accelerate drug development timelines, and support comprehensive laboratory workflows.
The life science instrumentation market faces significant challenges in emerging economies due to limited healthcare and research infrastructure, which restricts the adoption of advanced analytical, imaging, and automation technologies. Despite a growing demand driven by population growth, an increasing burden of chronic diseases, and rising healthcare investments, several factors hinder market penetration. These include inadequate laboratory capacity, a shortage of skilled professionals, limited funding, and inconsistent access to modern technologies. Additionally, high costs of instruments, maintenance limitations, and restrictions within reimbursement systems further slow down the adoption of these technologies. These barriers pose challenges for manufacturers in scaling operations, providing services, and offering training. Therefore, there is a critical need for sustained infrastructure development and the creation of localized, cost-effective solutions.
LIFE SCIENCE INSTRUMENTATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Leverages advanced diagnostic technologies such as mass spectrometry, next-generation sequencing, and clinical analyzers for early disease detection, biomarker discovery, and personalized treatment planning. | Improved diagnostic accuracy, faster clinical decision-making, enhanced patient outcomes, and leadership in precision medicine. |
|
|
Utilizes chromatography, mass spectrometry, and cell analysis systems in drug discovery, biologics development, and quality control of vaccines and therapeutics. | Accelerated R&D timelines, higher success rates in drug development, robust quality assurance, and faster time-to-market for new medicines. |
|
|
Applies spectroscopy, chromatography, and mass spectrometry to analyze food composition, detect contaminants, and ensure safety and nutritional quality across its global supply chain. | Enhanced food safety, consistent product quality, regulatory compliance, and strengthened consumer trust and brand reputation. |
|
|
Deploys advanced analytical instrumentation such as mass spectrometry, gas chromatography, and molecular spectroscopy for environmental testing, food analysis, and pharmaceutical quality services. | High-precision testing, faster turnaround times, regulatory compliance support for clients, and expanded service capabilities across multiple industries. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The life science instrumentation ecosystem connects leading manufacturers like Thermo Fisher Scientific and Danaher Corporation with material suppliers such as DuPont and 3M, all operating under strict oversight from regulators like the US Food and Drug Administration and the International Organization for Standardization. These instruments are widely used by end users including Pfizer, Mayo Clinic, and Nestlé, creating an integrated, innovation-driven ecosystem that supports advancements in healthcare, research, food safety, and environmental monitoring.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The spectroscopy segment is a major growth driver in the life science instrumentation market, fueled by increasing demand for precise molecular characterization and advanced biomolecular analysis across research and clinical applications. Continuous technological advancements, including high-resolution detectors, advanced laser sources, and automation, are significantly enhancing the sensitivity, speed, and efficiency of spectroscopic instruments, enabling more reliable and high-throughput workflows. The rapid expansion of omics fields such as proteomics, metabolomics, and structural biology is further accelerating the adoption of techniques like mass spectrometry, Raman spectroscopy, and infrared spectroscopy for detailed chemical and biological profiling. In addition, the growing focus on personalized medicine, along with stringent quality control requirements in biopharmaceutical manufacturing and regulatory compliance in clinical diagnostics, is driving widespread integration of spectroscopy technologies across laboratories, research institutions, and industrial settings, thereby sustaining strong market growth.
The growth of spectroscopy instrumentation in life science research is driven by the increasing focus on understanding complex biological systems through genomics, proteomics, and metabolomics, all of which rely heavily on advanced analytical technologies for detailed molecular characterization. Rising investments from academic institutions, government bodies, and public–private research collaborations are further accelerating the adoption of high-performance spectroscopic instruments. At the same time, continuous technological advancements, including automation, miniaturization, AI-driven data analysis, and integrated laboratory platforms, are enhancing the accuracy, speed, and reproducibility of research workflows. These developments are positioning spectroscopy as a critical enabler of scientific discovery, innovation, and translational research, thereby driving sustained growth in the life science instrumentation market.
The pharmaceutical & biotechnology companies segment is a key end user in the life science instrumentation market, driven by strong demand for drug discovery, biologics, and vaccine development. These companies use advanced tools like chromatography, mass spectrometry, and cell analysis systems for research, testing, and quality control. Growth is supported by increasing focus on precision medicine, strict regulatory requirements, and rising investments in biopharma R&D, along with expanded outsourcing to CROs and CDMOs.
REGION
Asia Pacific to be fastest-growing region in global life science instrumentation market during forecast period
The Asia Pacific region is experiencing strong growth in the life science instrumentation market, driven by expanding pharmaceutical and biotechnology industries, rising R&D investments, and improving healthcare infrastructure. Countries like China, India, Japan, and South Korea are leading adoption due to increasing drug discovery activities, growing clinical diagnostics demand, and government support for life sciences. Additionally, outsourcing to CROs/CDMOs and rising use of advanced technologies are further boosting market expansion in the region.
LIFE SCIENCE INSTRUMENTATION MARKET: COMPANY EVALUATION MATRIX
The positioning chart indicates a clear company elevation trajectory from “Participants” toward “Stars,” driven by improvements in both product footprint and market share rank. Companies located in the lower-left quadrant remain early-stage or niche players with limited reach, while those progressing rightward demonstrate expanding portfolios and stronger commercialization capabilities. The upper-right quadrant where leaders like Agilent Technologies are positioned reflects firms that have successfully combined broad product offerings with high market penetration, signaling strong competitive maturity. Meanwhile, companies such as Merck KGaA, positioned closer to the upper-left, show solid market presence but comparatively narrower product footprints, suggesting opportunities for portfolio expansion. Overall, the figure highlights a gradual elevation path where innovation, strategic partnerships, and portfolio diversification are key levers enabling companies to move upward and rightward into leadership positions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies Inc. (US)
- Shimadzu Corporation (Japan)
- Danaher Corporation (US)
- Waters Corporation (US)
- Becton, Dickinson and Company (US)
- PerkinElmer (US)
- Bruker (US)
- Bio-Rad Laboratories, Inc (US)
- QIAGEN (Germany)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 63.40 Billion |
| Market Forecast in 2031 (Value) | USD 92.53 Billion |
| Growth Rate | CAGR of 6.5% from 2025–2031 |
| Years Considered | 2023–2031 |
| Base Year | 2024 |
| Forecast Period | 2025–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: LIFE SCIENCE INSTRUMENTATION MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Requirement for compact and space-efficient instruments for smaller lab setups | Benchtop and miniaturized instrument designs without compromising performance | Better space utilization, cost savings on infrastructure, and suitability for decentralized or mobile labs |
RECENT DEVELOPMENTS
- March 2026 : Agilent introduced its Infinity III LC Series at San Antonio, featuring the 1290 and 1260 Infinity III platforms with built-in InfinityLab Assist Technology for automated troubleshooting, diagnostics, maintenance guidance, and remote alerts. The system also offers biocompatible options, while the 1290 Infinity III Hybrid Multisampler adds a new Feed Injection mode to reduce strong solvent effects and improve injection performance.
- March 2026 : Agilent Technologies announced the acquisition of Biocare Medical in a USD 950 million all-cash deal, integrating its cancer and infectious disease diagnostic products into its Life Sciences and Diagnostics unit to boost revenue and profitability within a year.
- October 2025 : Waters Corporation launched the Xevo Charge Detection Mass Spectrometer (CDMS), offering unprecedented measurement and characterization capabilities for large biomolecules essential to next-generation therapeutics and structural biology.
- June 2025 : Agilent Technologies introduced the InfinityLab Pro iQ Series at ASMS 2025, marking the next generation of LC-mass detection systems. The series offers enhanced sensitivity and performance for analyzing oligonucleotides, peptides, and proteins, along with intelligent features for real-time monitoring, simplified maintenance, and reduced downtime.
- June 2025 : Thermo Fisher Scientific unveiled next-generation instruments and software solutions for omics, biopharma, and environmental workflows, marking a major leap in analytical performance aimed at uncovering complex biological processes and advancing disease, environmental, and food safety research.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
MARKET DYNAMICS
4.1.1
DRIVERS
4.1.2
RESTRAINTS
4.1.3
OPPORTUNITIES
4.1.4
CHALLENGES
4.2
UNMET NEEDS & WHITE SPACES
4.3
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
BARGAINING POWER OF SUPPLIERS
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL LIFE SCIENCE INSTRUMENTATION INDUSTRY
5.2.4
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
SUPPLY CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.6
PRICING ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF LIFE SCIENCE INSTRUMENTATION TECHNOLOGIES, BY KEY PLAYER (2023–2025)
5.6.2
AVERAGE SELLING PRICE TREND OF LIFE SCIENCE INSTRUMENTATION TECHNOLOGIES, BY REGION (2023–2025)
5.7
TRADE ANALYSIS
5.7.1
EXPORT SCENARIO
5.7.2
IMPORT SCENARIO
5.8
KEY CONFERENCES & EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10
INVESTMENT & FUNDING SCENARIO
5.11
CASE STUDY ANALYSIS
5.12
IMPACT OF 2025 US TARIFFS ON LIFE SCIENCE INSTRUMENTATION MARKET
5.12.1
INTRODUCTION
5.12.2
KEY TARIFF RATES
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRY/REGION
5.12.4.1
US
5.12.4.2
EUROPE
5.12.4.3
ASIA PACIFIC
5.12.5
IMPACT OF END-USE INDUSTRIES
6
STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.4
PATENT ANALYSIS
6.5
IMPACT OF AI/GEN AI ON LIFE SCIENCE INSTRUMENTATION MARKET
6.5.1
TOP USE CASES & MARKET POTENTIAL
6.5.2
BEST PRACTICES IN LIFE SCIENCE INSTRUMENTATION MARKET
6.5.3
CASE STUDIES OF AI IMPLEMENTATION IN LIFE SCIENCE INSTRUMENTATION MARKET
6.5.4
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN LIFE SCIENCE INSTRUMENTATION MARKET
6.6
SUCCESS STORIES & REAL-WORLD APPLICATIONS
7
REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
LIFE SCIENCE INSTRUMENTATION MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031-IN VALUE, USD MILLION)
9.1
SPECTROSCOPY
9.1.1
MASS SPECTROMETERS
9.1.2
MOLECULAR SPECTROMETERS
9.1.3
ATOMIC SPECTROMETERS
9.2
CHROMATOGRAPHY
9.2.1
LIQUID CHROMATOGRAPHY SYSTEMS
9.2.2
GAS CHROMATOGRAPHY SYSTEMS
9.2.3
SUSPERCRITICAL FLUID CHROMATOGRAPHY SYSTEMS
9.2.3
THIN-LAYER CHROMATOGRAPHY SYSTEMS
9.3
POLYMERASE CHAIN REACTION (PCR)
9.3.1
QUANTITATIVE PCR (QPCR)
9.3.2
DIGITAL PCR (DPCR)
9.3.3
OTHER PCR TECHNOLOGIES
9.4
IMMUNOASSAYS
9.5
LYOPHILIZATION
9.5.1
TRAY-STYLE FREEZE DRYERS
9.5.2
MANIFOLD FREEZE DRYERS
9.5.3
SHELL (ROTARY) FREEZE DRYERS
9.6
LIQUID HANDLING SYSTEMS
9.6.1
ELECTRONIC LIQUID HANDLING SYSTEMS
9.6.2
AUTOMATED LIQUID HANDLING SYSTEMS
9.6.3
MANUAL LIQUID HANDLING SYSTEMS
9.7
CLINICAL CHEMISTRY ANALYZERS
9.8
MICROSCOPY
9.8.1
OPTICAL MICROSCOPES
9.8.2
ELECTRON MICROSCOPES
9.8.3
SCANNING PROBE MICROSCOPES
9.8.4
OTHER MICROSCOPES
9.9
FLOW CYTOMETRY
9.9.1
CELL ANALYZERS
9.9.2
CELL SORTERS
9.10
NEXT-GENERATION SEQUENCING (NGS)
9.11
CENTRIFUGES
9.11.1
MICROCENTRIFUGES
9.11.2
MULTIPURPOSE CENTRIFUGES
9.11.3
MINICENTRIFUGES
9.11.4
ULTRCENTRIFUGES
9.12
ELECTROPHORESIS
9.12.1
GEL ELECTROPHORESIS SYSTEMS
9.12.2
CAPILLARY ELECTROPHORESIS SYSTEMS
9.13
CELL COUNTERS
9.13.1
AUTOMATED CELL COUNTERS
9.13.2
HEMOCYTOMETERS & MANUAL CELL COUNTERS
9.14
OTHER TECHNOLOGIES
9.14.1
LABORATORY FREEZERS
9.14.1.1
FREEZERS
9.14.1.2
REFRIGERATORS
9.14.2
HEAT STERILIZATION
9.14.2.1
MOIST HEAT/STEAM STERILIZATION INSTRUMENTS
9.14.2.2
DRY HEAT STERILIZATION INSTRUMENTATION
9.14.3
MICROPLATE SYSTEMS
9.14.3.1
MICROPLATE READERS
9.14.3.2
MICROPLATE DISPENSERS
9.14.3.3
MICROPLATE WASHERS
9.14.4
LABORATORY BALANCES & SCALES
9.14.5
COLORIMETERS
9.14.6
INCUBATORS
9.14.7
FUME HOODS
9.14.8
ROBOTIC SYSTEMS
9.14.8.1
ROBOTIC ARMS
9.14.8.2
TRACK ROBOT SYSTEMS
9.14.9
PH METERS
9.14.10
CONDUCTIVITY & RESISTIVITY METERS
9.14.11
DISOLVED CO2 & O2 METERS
9.14.12
TITRATORS
9.14.13
GAS ANALYZERS
9.14.14
TOC ANALYZERS
9.14.15
THERMAL ANALYZERS
9.14.16
SHAKERS/ROTATORS AND STIRRERS
10
LIFE SCIENCE INSTRUMENTATION MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
10.1
RESEARCH APPLICATIONS
10.2
CLINICAL & DIAGNOSTIC APPLICATIONS
10.3
OTHER APPLICATIONS
11
LIFE SCIENCE INSTRUMENTATION MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
11.1
HOSPITALS & DIAGNOSTIC LABORATORIES
11.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3
ACADEMIC & RESEARCH INSTITUTES
11.4
AGRICULTURE & FOOD INDUSTRIES
11.5
ENVIRONMENTAL TESTING LABORATORIES
11.6
CLINICAL RESEARCH ORGANIZATIONS
11.7
OTHER END USERS
12
LIFE SCIENCE INSTRUMENTATION MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
12.1
INTRODUCTION
12.2
NORTH AMERICA
12.2.1
US
12.2.2
CANADA
12.3
EUROPE
12.3.1
GERMANY
12.3.2
UK
12.3.3
FRANCE
12.3.4
ITALY
12.3.5
SPAIN
12.3.6
REST OF EUROPE
12.4
ASIA PACIFIC
12.4.1
CHINA
12.4.2
JAPAN
12.4.3
INDIA
12.4.4
SOUTH KOREA
12.4.5
AUSTRALIA
12.4.6
REST OF ASIA PACIFIC
12.5
LATIN AMERICA
12.5.1
BRAZIL
12.5.2
MEXICO
12.5.3
REST OF LATIN AMERICA
12.6
MIDDLE EAST & AFRICA
12.6.1
GCC COUNTRIES
12.6.2
REST OF MIDDLE EAST & AFRICA
13
COMPETITIVE LANDSCAPE
13.1
INTRODUCTION
13.2
KEY PLAYER STRATEGIES/RIGHT TO WIN (2021–2025)
13.3
REVENUE ANALYSIS (2021–2025)
13.4
MARKET SHARE ANALYSIS,
13.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
13.5.1
STARS
13.5.2
EMERGING LEADERS
13.5.3
PERVASIVE PLAYERS
13.5.4
PARTICIPANTS
13.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
13.5.5.1
COMPANY FOOTPRINT
13.5.5.2
REGION FOOTPRINT
13.5.5.3
TECHNOLOGY FOOTPRINT
13.5.5.5
APPLICATION FOOTPRINT
13.5.5.6
END-USER FOOTPRINT
13.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
13.6.1
PROGRESSIVE COMPANIES
13.6.2
RESPONSIVE COMPANIES
13.6.3
DYNAMIC COMPANIES
13.6.4
STARTING BLOCKS
13.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
13.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
13.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
13.7
C0MPETITIVE SCENARIO
13.7.1
NEW PRODUCT LAUNCHES & APPROVALS
13.7.2
DEALS
13.7.3
OTHER DEVELOPMENTS
13.8
BRAND/PRODUCT COMPARISON PRODUCT COMPARISON
13.9
COMPANY VALUATION & FINANCIAL METRICS
14
COMPANY PROFILES
14.1
KEY PLAYERS
14.1.1
AGILENT TECHNOLOGIES
14.1.2
BRUKER
14.1.3
BECTON, DICKINSON AND COMPANY
14.1.4
BIO-RAD LABORATORIES
14.1.5
DANAHER
14.1.6
EPPENDORF
14.1.7
HORIBA
14.1.8
HITACHI-HIGH-TECHNOLOGIES CORPORATION
14.1.9
JOEL LTD.
14.1.10
MERCK KGAA
14.1.11
PERKINELMER
14.1.12
QIAGEN N.V
14.1.13
SHIMADZU CORPORATION
14.1.14
THERMO FISHER SCIENTIFIC
14.1.15
WATERS CORPORATION
14.2
OTHER PLAYERS
14.2.1
AVANTOR
14.2.2
ACCU-SCOPE
14.2.3
BIOMERIEUX S.A
14.2.4
CARL ZEISS AG
14.2.5
CLEAVER SCIENTIFIC
14.2.6
GILSON INCORPORATED
14.2.7
GL SCIENCES INC.
14.2.8
HYRIS
14.2.9
ILLUMINA INC.
14.2.10
MOTIC GROUP
14.2.11
OLYMPUS CORPORATION
14.2.12
OXFORD INSTRUMENTS
14.2.13
PANOMEX INC.
14.2.14
SIGMA LABORZENTRIFUGEN GMBH
14.2.15
TECAN TRADING AG
15
RESEARCH METHODOLOGY
15.1
RESEARCH DATA SOURCES
15.1.1
SECONDARY RESEARCH
15.1.2
PRIMARY RESEARCH
15.1.2.1
PRIMARY SOURCES
15.1.2.2
KEY INDUSTRY INSIGHTS
15.1.2.3
BREAKDOWN OF PRIMARIES
15.2
MARKET SIZE ESTIMATION METHODOLOGY
15.2.1
REVENUE MAPPING-BASED MARKET ESTIMATION
15.2.2
END-USER-BASED MARKET ESTIMATION
15.3
MARKET FORECASTING APPROACH
15.4
MARKET BREAKDOWN & DATA TRIANGULATION
15.5
RESEARCH ASSUMPTIONS
15.6
RESEARCH LIMITATIONS
15.6.1
SCOPE-RELATED LIMITATIONS
15.6.2
METHODOLOGY-RELATED LIMITATIONS
15.7
RISK ASSESSMENT
16
APPENDIX
16.1
DISCUSSION GUIDE
16.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3
CUSTOMIZATION OPTIONS
16.4
RELATED REPORTS
16.5
AUTHOR DETAILS
Methodology
The study involved four major activities in estimating the current size of the life science instrumentation market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial life science instrumentation market study. It was also used to obtain important information on key players, market classification & segmentation aligned with industry trends to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources on the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and other key executives from leading companies and organizations in the life science instrumentation market. The demand-side primary sources include pharma-biopharma companies, CDMOs, research labs, F&B companies, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 4 billion, Tier 2 = USD 1-2 Billion, and Tier 3 = <USD 1 Billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the life science instrumentation market size was determined using the revenue share analysis of leading players. For this purpose, key market players were identified, and their revenues from the market were determined using insights gathered during the primary and secondary research phases. Secondary research included analyzing the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, including CEOs, directors, and senior marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:
- Generating a list of major global players operating in the life science instrumentation market
- Mapping annual revenues generated by major global players from the technology segment (or nearest reported business unit/product category)
- Revenue mapping of major players to cover a major share of the global market, as of 2025
- Extrapolating the global value of the life science instrumentation market industry.
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the global life science instrumentation market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the life science instrumentation market was validated using top-down and bottom-up approaches.
Market Definition
Life science techniques encompass a variety of analytical and experimental methodologies including chromatography, spectroscopy, electrophoresis, PCR, and flow cytometry used to study living organisms. These techniques have broad applications across pharmaceuticals and biotechnology, clinical diagnostics, food and beverage testing, environmental monitoring, and industrial chemistry. They are also widely utilized by academic and research institutions as well as forensic laboratories. Overall, these technologies enable scientists to analyze and understand cellular functions and biological systems more effectively.
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Biotechnology and Pharmaceutical Companies and CROs
- Laboratory Technicians and Workers
- Life Science Instruments Manufacturers, Vendors, and Distributors
- Venture Capitalists and Other Government Funding Organizations
- Research and Consulting Firms
- Healthcare Equipment or Product Suppliers and Distributors
- Group Purchasing Organizations (GPOs)
- Academic Universities and Medical Research Centers
- Environmental Testing Laboratories
- Food and Beverage Testing Centers
- Hospitals and Diagnostic Centers
- Clinical Research Organizations
- R&D Centers
- Business Research and Consulting Firms
- Medical Research Laboratories
- R&D Departments
- Finance/Procurement Departments
Report Objectives
- To define, describe, and forecast the size of the life science instrumentation market based on technology, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global life science instrumentation market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the global life science instrumentation market
- To analyze key growth opportunities in the global life science instrumentation market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Australia, South Korea, and the RoAPAC), Latin America (Brazil, Mexico, and the RoLATAM), and the Middle East & Africa
- To profile the key players in the life science instrumentation market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global life science instrumentation market, such as product launches, agreements, expansions, and mergers & acquisitions
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to the company’s specific needs. The following customization options are available for the present global life science instrumentation market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to five)
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Life Science Instrumentation Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
Life Science Instrumentation Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
Explore Life Science Instrumentation Intelligence
Powered by 17 years of MarketsandMarkets intelligence
